Pneumococcal vaccine polyvalent; contains a total of 575mcg polysaccharides per 0.5mL; soln for IM or SC inj; contains phenol. Pneumovax 23 induces type-specific antibodies that enhance opsonization, ...

Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114. Merck announced positive topline results ...

Please provide your email address to receive an email when new articles are posted on . There were less than 0.2 cases of injection site necrosis per million 23-valent pneumococcal vaccine doses.

WHITEHOUSE STATION, N.J., Aug 13, 2014 (BUSINESS WIRE) -- Merck MRK +1.47% , known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for ...

One of Merck’s next-generation pneumococcal vaccines has sailed through a mid-stage trial and is being readied for a phase 3 study next month. V116—one of three pneumococcal vaccines in Merck’s ...

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...

All adults aged 65 years and older should now receive the 13-valent pneumococcal conjugate vaccine (PCV13/Prevnar 13, Wyeth), in addition to the 23-valent pneumococcal polysaccharide vaccine ...

A US Food and Drug Administration (FDA) investigation of injection-site necrosis in some people who received the 23-valent pneumococcal vaccine has concluded that the benefits of the vaccine outweigh ...

PNEUMOVAX 23 contains a mixture of inactive parts from 23 of the most common types of pneumococcal bacteria. PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of germs ...